Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (NCT07299019) titled 'A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis' on Dec. 18, 2025.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: Zenas BioPharma (USA), LLC
Condition:
Secondary Progressive Multiple Sclerosis
Intervention:
Drug: Orelabrutinib
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: March 2026
Target Sample Size: 330
To know more, visit https://clinicaltrials.gov/stu...